NEW YORK — The US Food and Drug Administration last week granted Emergency Use Authorization for a PCR-based SARS-CoV-2 test developed by GK Pharmaceuticals Contract Manufacturing Operations (GK CMO).
The GK Accu-Right SARS-CoV-2 RT-PCR Kit is designed to detect two regions within the virus' nucleocapsid gene in upper respiratory specimens collected by a healthcare provider, such as nasopharyngeal, oropharyngeal, mid-turbinate, or nasal swabs.